AL-ADTRAN
16.5.2023 14:01:34 CEST | Business Wire | Press release
Adtran today launched a major upgrade of its Oscilloquartz aPNT+™ technology suite, bringing new levels of resilience to critical network infrastructure that relies on position, navigation and timing (PNT) services. With enhancements to its core, edge and access synchronization solutions, the portfolio provides operators of telecommunications, financial networks, power grids, defense infrastructure and more with the best available protection against GNSS vulnerabilities and cyberattacks. Adtran’s timing technology now leverages more sources of accurate and reliable timing and features new capabilities to detect disturbances and assure vital PNT services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230512005309/en/
Adtran’s Oscilloquartz aPNT+™ platform is a vital tool for keeping critical infrastructure safe and online. (Photo: Business Wire)
“From 5G connectivity to air traffic control, accurate and reliable PNT services are crucial for the safety, efficiency and optimal performance of a wide range of modern applications. That’s why the enhancements we’ve made to our aPNT+™ platform are so significant. These include improved jamming and spoofing detection using a unique, highly advanced, dedicated algorithm to ensure maximum resilience against any intentional or unintentional interference,” said Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “Our upgraded portfolio is a significant step up for critical network timing. It provides unparalleled precision and reliability even in the most challenging environments, including situations where GNSS is disrupted for extended periods.”
Adtran’s OSA 5401 and 5405 access network synchronization solutions now feature the same advanced jamming and spoofing detection capabilities as its core and edge products. Additionally, the OSA 5405-MB, a compact and integrated outdoor multi-band GNSS receiver and PTP grandmaster, has been upgraded with improved multi-band capabilities. As well as satellite constellations, including GPS, GLONASS, BeiDou and GALILEO, it now supports the Indian Regional Navigation Satellite System (IRNSS). This is critical for mobile network operators in the subcontinent, as the Indian government has ruled that smartphones must be compatible with the country’s home-grown GNSS system. Furthermore, the solution now utilizes a combination of L1 and L5 band signals to better mitigate disruption caused by environmental factors.
“Enhanced NTP functionality is another feature that makes our upgraded aPNT+™ platform even more powerful. Our standalone NTP servers can now support up to 500,000 transactions per second, providing unique NTP performance. This level of transaction handling is a significant advantage against DDoS attacks,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our core and edge grandmaster clocks are also more resilient than ever. With our multi-source ePRTC combiner, they can leverage up to five independent timing sources, which can include up to three high-performance optical cesium atomic clocks, to create a single super-resilient and highly reliable clock source. Customers can select from GNSS constellations, PTP inputs, and alternative PNT sources such as STL, which uses low Earth orbit satellites, or the terrestrial-based eLORAN. Both offer extra protection against jamming and spoofing attacks while extending the 100nsec holdover period.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
